Press Releases

Samsung Biologics announced today that it has reached an agreement with Biogen for the buyout of Biogen's stake in the Samsung Bioepis joint venture for USD $2.3 billion. The transaction is expected to boost earnings growth of Samsung Biologics on a consolidated basis, fully capitalizing on Samsung Bioepis' growth outlook. The Board of Directors of Samsung Biologics has approved the transaction, in which payment for the shares will be made in installments over the next two y

WCG, a leading provider of clinical trial solutions, today announced WCG Total Safety™, a first-of-its-kind, end-to-end solution for handling case processing, aggregate reporting, drug safety, and safety letter distribution for emerging biopharmaceutical companies. This new offering creates a next generation safety management workflow, which enables strict adherence to regulatory directives and guidance, backed by a vast team of industry-recognized safety experts to manage the process f

Biotage is pleased to announce the launch of a sophisticated well plate evaporator, the TurboVap® 96 Dual – a second-generation system with two separate, and independently controlled evaporation compartments, building upon the reputable foundation of the Biotage TurboVap® product line. The new TurboVap® 96 Dual has been designed to support enhanced well-plate evaporation within the sample preparation workflow. With its unique two in one functionality users can run

Sativus Tech Corp , the first-ever AgTech company that is developing the protocols to grow saffron using vertical farming technology, has begun an extensive rebranding effort in response to the evolving needs of the agricultural market and to accelerate the company’s growth strategy. The company began to shape its new corporate vision with the change of its name from Seedo Corp to Sativus Tech Corp. The new name allows the company to begin a new brand identity and business strategy to p

Ferrer, the international pharmaceutical laboratory based in Barcelona, has become a B Corp company thanks to its positive impact in society and on the planet. The company has exceeded global B Corp standards in terms of social and environment performance, transparency and corporate responsibility in all the territories in which it has a direct presence. With the completion of the certification process, Ferrer is the first Spanish pharmaceutical company to become part of the international B C

EdiGene, Inc., a global biotechnology company focused on translating gene-editing technologies into transformative therapies for patients with serious genetic diseases and cancer, announced a research and development collaboration with Haihe Laboratory of Cell Ecosystem to develop hematopoietic stem cell regenerative therapies and platform technology by combining resources and expertise from both sides. The Haihe Laboratory of Cell Ecosystem, run by the Institute of Hematology and B

Virica Biotech Inc., a leading developer of solutions for scaling of viral medicines, today announced it will collaborate with Oxford Biomedica plc, a leading gene and cell therapy company, to improve the yield and production efficiency of Oxford Biomedica’s next generation lentiviral vector gene therapies using Virica’s Viral Sensitizers (VSEs™). Ella Korets-Smith, Chief Business Officer of Virica Biotech, said: “There is growing demand from major industry p

Sonoma Pharmaceuticals, Inc.  a global healthcare leader developing and producing patented Microcyn® technology-based stabilized hypochlorous acid (HOCl) products for a wide range of applications, including wound, eye, oral and nasal care, disinfectant use and dermatological conditions, today announced that it has added Salus Medical as an additional distribution partner in the United States for dental care and expanded its oral and dental care lines to China via a partnership deal w

InterX Inc. have developed a polarizable force-field/simulation stack that is parameterized by ab-initio data and describes arbitrary neutral organic molecules. The simulation suite achieves solvation results better than chemical accuracy. These findings are published online in Nature Communications: https://www.nature.com/articles/s41467-022-28041-0 About InterX Inc. InterX Inc. is creating the technology to perform molecular simulations with chemi

IBM  and Francisco Partners, a leading global investment firm that specializes in partnering with technology businesses, today announced that the companies have signed a definitive agreement under which Francisco Partners will acquire healthcare data and analytics assets from IBM that are currently part of the Watson Health business. The assets acquired by Francisco Partners include extensive and diverse data sets and products, including Health Insights, MarketScan, Clinical Development,